Simon Allen
Nessuna posizione attualmente
Patrimonio netto: - $ in data 30/04/2024
Profilo
Simon Allen served as Chief Executive Officer at Kalypsys, Inc. and CohBar, Inc. He was also Chief Executive Officer & Executive Director at Anebulo Pharmaceuticals, Inc. Mr. Allen held the position of Chief Business Officer at Ambrx, Inc. for 12 years.
He was Vice President-Corporate Development at Nuvelo, Inc. and Manager-Business Development at Corixa Corp.
Mr. Allen also served as Vice President-Business Development at AGY Therapeutics, Inc. and Vice President-Business Development at Pacira Pharmaceuticals, Inc. (California).
He was Chief Commercial Officer at CovX Research LLC.
Mr. Allen earned an undergraduate degree from The University of Sydney and an MBA from the Australian Graduate School of Management.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 30/09/2023 | 0 ( -.--% ) | - $ | 30/04/2024 |
Precedenti posizioni note di Simon Allen
| Società | Posizione | Fine |
|---|---|---|
| ANEBULO PHARMACEUTICALS, INC. | Amministratore Delegato | 05/10/2023 |
Ambrx Biopharma, Inc.
 Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Corporate Officer/Principal | 01/01/2022 |
| AMBRX INC | Corporate Officer/Principal | 01/01/2022 |
| COHBAR, INC. | Amministratore Delegato | 07/12/2018 |
Kalypsys, Inc.
 Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | Presidente | 01/06/2010 |
Formazione di Simon Allen
| The University of Sydney | Undergraduate Degree |
| Australian Graduate School of Management | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| COHBAR, INC. | Health Technology |
| ANEBULO PHARMACEUTICALS, INC. | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| Aziende private | 8 |
|---|---|
| Nuvelo, Inc. | Health Technology |
Pacira Pharmaceuticals, Inc. (California)
 Pacira Pharmaceuticals, Inc. (California) Medical SpecialtiesHealth Technology Pacira Pharmaceuticals, Inc. develops and manufactures injectable and sustained release therapeutic products. It focuses on clinical and commercial development activities by understanding the needs of the acute care market. The company was founded in March 2007 and is headquartered in San Diego, CA. | Health Technology |
AGY Therapeutics, Inc.
 AGY Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AGY Therapeutics, Inc. develops new therapies for diseases and disorders. It develops central nervous system therapeutics for the treatments of neurodegenerative diseases, CNS injuries, stroke, and schizophrenia. The company was founded by Robert Swanson and Karoly Nikolich in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Corixa Corp.
 Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Health Technology |
Kalypsys, Inc.
Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | Health Technology |
Ambrx, Inc.
 Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
CovX Research LLC
 CovX Research LLC BiotechnologyHealth Technology Part of Pfizer Inc., CovX Research LLC is a company that manufactures biotherapeutics and medical products. The company is based in San Diego, CA. The company was founded by Richard Alan Lerner, Carlos F. Barbas. CovX Research was acquired by Pfizer Inc. from Tavistock Life Sciences Co. on January 31, 2008 for $230 million. | Health Technology |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Health Technology |
- Borsa valori
- Insiders
- Simon Allen
